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Inhibition of Insulin-Like Growth
Factor 1 Receptor Enhances the
Efficacy of Sorafenib in Inhibiting
Hepatocellular Carcinoma Cell
Growth and Survival
Fang Wang,1 Thomas Bank,1 Gregory Malnassy,1 Maribel Arteaga,1 Na Shang,1 Annika Dalheim,1 Xianzhong Ding,2
Scott J. Cotler,3 Mitchell F. Denning,2 Michael I. Nishimura,1 Peter Breslin,1,4 and Wei Qiu
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Hepatocellular carcinoma (HCC) is the ﬁfth most common primary cancer and second largest cause of cancer-related
death worldwide. The ﬁrst-line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced
HCC by less than 3 months. Most patients with advanced HCC have shown limited response rates and survival beneﬁts with sorafenib. Although sorafenib is an inhibitor of multiple kinases, including serine/threonine-protein kinase cRaf, serine/threonine-protein kinase B-Raf, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2,
VEGFR-3, and platelet-derived growth factor receptor b, HCC cells are able to escape from sorafenib treatment using
other pathways that the drug insufﬁciently inhibits. The aim of this study was to identify and target survival and proliferation pathways that enable HCC to escape the antitumor activity of sorafenib. We found that insulin-like growth
factor 1 receptor (IGF1R) remains activated in HCC cells treated with sorafenib. Knockdown of IGF1R sensitizes
HCC cells to sorafenib treatment and decreases protein kinase B (AKT) activation. Overexpression of constitutively
activated AKT reverses the effect of knockdown of IGF1R in sensitizing HCC cells to treatment with sorafenib. Further, we found that ceritinib, a drug approved by the U.S. Food and Drug Administration for treatment of non-small
cell lung cancer, effectively inhibits the IGF1R/AKT pathway and enhances the inhibitory efﬁcacy of sorafenib in
human HCC cell growth and survival in vitro, in a xenograft mouse model and in the c-Met/b-catenin-driven HCC
mouse model. Conclusion: Our study provides a biochemical basis for evaluation of a new combination treatment that
includes IGF1R inhibitors, such as ceritinib and sorafenib, in patients with HCC. (Hepatology Communications
2018;2:732-746)

H

epatocellular carcinoma (HCC) is the primary malignancy of the liver and is now
the second leading cause of cancer deaths
worldwide.(1) Low rates of early diagnosis coupled
with high mortality rates make it critical to develop
new treatment approaches to HCC.(2) The multikinase

inhibitor sorafenib is the ﬁrst-line treatment for
advanced HCC, but the clinical impact of sorafenib is
modest (2%-3.3% objective partial response rate, 54%71% disease stabilization rate, and a nearly 3-month
survival advantage over placebo).(3) Sorafenib suppresses tumor proliferation and angiogenesis by

Abbreviations: AKT, protein kinase B; ALK, anaplastic lymphoma kinase; CAT, Constitutively active b-catenin; c-Raf, serine/threonine-protein
kinase Raf-1; CMV, cytomegalovirus; ERK, extracellular signal-regulated kinase; FDA, U.S. Food and Drug Administration; GFP, green ﬂuorescent
protein; HCC, hepatocellular carcinoma; HSB2, sleeping beauty transposase 2; IGF1R, insulin-like growth factor 1 receptor; MET, c-met; p-, phosphorylated; PI3K, phosphatidylinositol 3-kinase; SCID, severe combined immunodeﬁciency mice; shRNA, short hairpin RNA; TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling; VEGF, vascular endothelial growth factor.
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inhibiting multiple serine/threonine and receptor tyrosine kinases, including serine/threonine-protein kinase
Raf-1 (or c-Raf), wild-type and mutant B-Raf, vascular endothelial growth factor receptor (VEGFR)-1,
VEGFR-2, VEGFR-3, platelet-derived growth factor
receptor b, tyrosine-protein kinase Kit (c-KIT), FMSlike tyrosine kinase 3 (FLT-3), and proto-oncogene
tyrosine-protein kinase receptor Ret (RET).(4) However, other signaling pathways that sorafenib fails to
inhibit can contribute to cell growth and survival in
sorafenib-acquired resistant cells, such as the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)
signaling pathway.(5) Therefore, combination drug
treatment to inhibit the remaining active cell survival
and growth pathways appears to be a promising
approach to improve sorafenib efﬁcacy.(6,7)
Insulin-like growth factor 1 receptor (IGF1R) is a
receptor for IGF. IGF1R is activated through ligandinduced phosphorylation and subsequently phosphorylates and activates both the PI3K/AKT and Ras/mitogen-activated protein kinase pathways.(8) Activation of
IGF1R is crucial for malignant transformation and the
survival of malignant cells.(8-10) For example, aberrant
expression and activation of IGF1R contributes to
increased survival of pancreatic cancer cells,(11) and
knockdown of IGF1R led to inhibition of proliferation, migration, and invasiveness of prostate cancer
cells.(12) Overexpression of IGF1R was detected in
33% of human HCCs, and increased activation of
IGF1R was observed in 52% of HCC tumors.(13)
Abrogation of IGF1R activation signiﬁcantly but
modestly decreases HCC cell viability and proliferation.(14) Although several IGF1R inhibitors have been
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tested in clinical trials,(9,15,16) none have been approved
by the U.S. Food and Drug Administration (FDA).
Intriguingly, ceritinib (Zykadia), a potent anaplastic
lymphoma kinase (ALK) inhibitor that is FDA
approved for treatment of non-small cell lung
cancer,(17) has been reported to effectively inhibit
IGF1R.(18)
In this study, we found that IGF1R remains activated in HCC cells after treatment with sorafenib.
Moreover, knockdown of IGF1R sensitizes HCC cells
to sorafenib by decreasing AKT activation. Overexpression of constitutively activated AKT reverses the
effect of IGF1R knockdown in sensitizing HCC cells
to sorafenib treatment. Furthermore, we found that
ceritinib decreases phosphorylation of IGF1R and
AKT and enhances the efﬁcacy of inhibition by sorafenib in human HCC cell growth and survival in in vitro
and in vivo models. Our study provides evidence that
the combination of ceritinib and sorafenib has therapeutic potential for HCC and elucidates its possible
mechanisms.

Materials and Methods
CELLS AND REAGENTS
Huh7 cells were purchased from the Japanese Collection of Research Bioresources Cell Bank. Hep3B,
HepG2, and 293T cells were purchased from the
American Type Culture Collection. All cells were cultured with Dulbecco’s modiﬁed Eagle’s medium (high
glucose; Thermo Scientiﬁc, Waltham, MA), supplemented with 10% fetal bovine serum (Tissue Culture

C 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of
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Biologicals) and penicillin and streptomycin (SigmaAldrich, St. Louis, MO) in a humidiﬁed atmosphere
of 5% CO2 at 378C. Cells were plated in 12 or 6-well
plates at 30%-40% density for 24 hours prior to treatment. Ceritinib was purchased from LC Laboratories
(Cat#2086; Woburn, MA), and sorafenib was purchased from MedKoo Bioscience (Cat#100770a; Morrisville, NC).

MICE
All animals received humane care according to the
Guide for the Care and Use of Laboratory Animals
(http://oacu.od.nih.gov/ac_cbt/guide3.htm). The procedures for all animal experiments were approved by
the Institutional Animal Care and Use Committee of
Loyola University Chicago. The mice were housed in
micro-isolator cages in a room illuminated from 7:00
AM to 7:00 PM (12-hour:12-hour light–dark cycle) and
allowed access to water and chow ad libitum. C57BL/6
mice were obtained from the Jackson Laboratory, and
severe combined immunodeﬁciency mice (SCID-bg)
were purchased from Charles River.

CELL PROLIFERATION/VIABILITY
ANALYSIS BY ALAMARBLUE
ASSAY
Hep3B, Huh7, and HepG2 cells were seeded into
96-well plates (5 3 103 cells/well). After 24 hours,
cells were treated with ceritinib (0.5-1.5 lM), sorafenib (1.25-5.0 lM), or both. At different time points,
culture media was removed and alamarBlue
(BUF012A; Bio-Rad, Hercules, CA) solution (1:10
dilution in phosphate-buffered saline) was added to
the cells. After a 2-hour incubation at 378C, ﬂuorescence values were measured with a ﬂuorescent plate
reader at 530-560 nm excitation/590 nm emission.

LENTIVIRAL PARTICLE
PREPARATION
For IGF1R knockdown experiments, Hep3B cells
were infected with lentiviral plasmid (p)LKO.1 particles that contained IGF1R or scrambled short hairpin
(sh) RNA and selected with 2 lg/mL puromycin for
5 days. Lentiviral pLKO.1 plasmids for shIGF1R
(Table 1) or scrambled shRNA (SHC002; SigmaAldrich) were packaged with the cytomegalovirus plasmid (pCMV)-dr8.2 (Addgene) and pCMV-VSVG
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(Addgene) in 293T cells to produce lentiviral particles
as described.(19,20)
For overexpression of constitutively active AKT
experiments, Hep3B cells were infected with lentiviral
particles packaged with FG12-cmv-green ﬂuorescent
protein (gfp)-akt (constitutively active AKT) or
FG12-cmv-gfp, pCMVD8.71, and pMD.G in 293T
cells. Six days after infection, GFP-positive cells
expressing constitutively active AKT were sorted by
ﬂow cytometry (FACSAria Cell Sorter).

COLONY FORMATION ASSAY
Hep3B cells were seeded into 12-well plates (6 3
103 cells/well) for 24 hours before treatment as
described.(21) After 48 hours of treatment with
dimethyl sulfoxide, 1.25 lM sorafenib, 0.5 lM ceritinib, or a combination of both drugs, media was
changed and the cells were cultured for 14 days. Cells
were ﬁxed in a mixture of 6.0% glutaraldehyde and
stained with 0.5% crystal violet. Colonies were scored
in at least four ﬁelds (magniﬁcation 340) and reported
as means 6 SD.

XENOGRAFT MODEL
SCID-bg mice were shaved following anesthesia
using isoﬂurane, and 5 3 106 Hep3B cells in 100 lL
of serum-free media was injected into the left or right
ﬂanks of the mice. Two weeks postinjection, mice
were treated with vehicle (30% captisol), ceritinib (25
mg/kg), sorafenib (25 mg/kg), or a combination of sorafenib (25 mg/kg) and ceritinib (25 mg/kg) by oral
gavage daily. Tumor volumes were measured daily
using a caliper until the day of sacriﬁce. Tumor volume
was calculated using the ellipsoidal formula as follows:
tumor volume (mm3) 5 1/2(L 3 W2), where L is the
greatest longitudinal distance of the tumor and W is
the greatest transverse distance of the tumor. Tumors
were harvested prior to volume growth beyond the
humane threshold of 1,500 mm3.

MET/CAT-DRIVEN HCC MODEL
For the c-met (MET)/constitutively active b-catenin (CAT)-driven HCC model,(19,22-24) 55 lg of total
plasmids, encoding the sleeping beauty transposase
(HSB2) and transposons with oncogenes MET/CAT
and gaussia luciferase (Gluc) (22.5 lg pT3-EF1a-cMET [human], 22.5 lg pT3-EF1a-DN90-b-catenin
[human], 5 lg pT3-Gluc1, and 5 lg HSB2) were
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TABLE 1. SHIGF1R SEQUENCES
Sequences

RNA Interference
Consortium Number

Company

CCGGCGGCAACCTGAGTTACTACATCTCGAGATGTAGTAACTCAGGTTGCCGTTTTTG
CCGGGCCGAAGATTTCACAGTCAAACTCGAGTTTGACTGTGAAATCTTCGGCTTTTTG

TRCN0000121301
TRCN0000039675

Sigma-Aldrich
Sigma-Aldrich

Target
Human shIGF1R-1
Human shIGF1R-2

injected hydrodynamically into age- and sex-matched
mice. Six weeks after MET/CAT injection, mice were
treated with vehicle (30% captisol), ceritinib (25 mg/
kg), sorafenib (25 mg/kg), or a combination of ceritinib and sorafenib by oral gavage daily for 4 weeks prior
to being sacriﬁced. All mice were maintained on the
standard diet. Liver and body weights of each mouse
were measured and recorded.

WESTERN BLOTTING
Western blotting was performed as described.(19,25)
Primary antibodies, including those for IGF1R,
phosphorylated IGF1R, caspase-3, active caspase-3,
poly(adenosine diphosphate ribose) polymerase, phosphorylated (p-)AKT (ser473), AKT, p-extracellular
signal-regulated kinase (ERK), and ERK, were purchased from Cell Signaling Technology (Danvers,
MA). Glyceraldehyde 3-phosphate dehydrogenase
and b-actin antibodies were purchased from Sigma.
More detailed information can be found in Table 2.

Ki67 IMMUNOHISTOCHEMICAL
STAINING
Immunohistochemistry
was
performed
as
described.(25) Detailed antibody information can be
found in Table 2. Cells with positive staining were
scored in at least ﬁve ﬁelds (magniﬁcation 3400) and
TABLE 2. ANTIBODIES USED IN THIS STUDY
Antibody
Phospho-IGF1R (Tyr1131)
IGF1R
Phospho-AKT (Ser473)
AKT
Phospho-ERK(Thr 202/Tyr 204)
ERK
Caspase 3
Cleavage caspase 3
PARP
GAPDH
b-actin
Ki67

Catalog Number

Company

3021
3027
4060
9272
4370
4695
9662
9661
9532
G8795
A5441
RM-9106-S0

Cell Signaling
Cell Signaling
Cell signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Sigma-Aldrich
Sigma-Aldrich
Fisher Scientific

Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PARP, poly(adenosine diphosphate ribose) polymerase;
Phospho, phosphorylated.

reported as means 6 SD. Three mice were used in
each group.

TERMINAL DEOXYNUCLEOTIDYL
TRANSFERASE–MEDIATED
DEOXYURIDINE TRIPHOSPHATE
NICK-END LABELING
Terminal deoxynucleotidyl transferase–mediated
deoxyuridine triphosphate nick-end labeling (TUNEL)
staining was performed as described(26) using a kit purchased from Millipore (Cat#S7101). The TUNELpositive cell numbers were scored in at least ﬁve ﬁelds
(magniﬁcation 3400) per mouse and are reported as
means 6 SD. Three mice were used in each group.

STATISTICAL ANALYSIS
Statistical analysis was carried out using GraphPad
Prism V software. Data are presented as means 6 SD
(shown in the ﬁgures where applicable). Statistical
signiﬁcance was calculated with the Student t test, and
P < 0.05 was considered signiﬁcant.

Results
KNOCKDOWN OF IGF1R
ENHANCES THE INHIBITION
EFFICACY OF SORAFENIB ON
HCC CELL GROWTH BY
INHIBITING AKT
Although sorafenib inhibits multiple kinase activities to suppress tumor angiogenesis and proliferation,
other signaling pathways, such as PI3K/AKT, which
sorafenib does not inhibit at low or even higher doses,
contribute to cell growth and survival in sorafenibacquired resistant cells.(5) The IGF1R signal pathway
has been reported to be enriched in sorafenib-acquired
resistant tumor cells.(27) Therefore, we examined
whether IGF1R remains active after sorafenib treatment in HCC cells. We found that sorafenib failed to
inhibit IGF1R phosphorylation at Tyr1131, which is
required for activation of IGF1R’s kinase,(28) in three
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FIG. 1. Knockdown of IGF1R enhanced the inhibitory efﬁcacy of sorafenib in HCC cells by inhibiting AKT. (A) HCC cells were
treated with sorafenib (1.25 lM for Hep3B, 2.5 lM for HepG2, and 5 lM for Huh7) for 24 hours. Expressions of p-IGF1R,
IGF1R, p-AKT (ser473), AKT, p-ERK, ERK, and GAPDH proteins were examined by western blotting. (B) Expressions of
IGF1R, p-AKT (ser473), AKT, p-ERK, ERK, and GAPDH proteins were examined by western blotting in Hep3B cells infected
with IGF1R shRNAs and scrambled shRNA lentiviral particles. (C) Cell proliferation was analyzed by the alamarBlue assay in
Hep3B cells infected with IGF1R shRNAs and scrambled shRNA lentiviral particles and then treated with 1.25 lM sorafenib. (D)
Expressions of IGF1R, AKT, and GAPDH proteins were examined by western blotting in Hep3B cells infected with scrambled
shRNA, IGF1R shRNA, constitutively active AKT, or both lentiviral particles. (E) Cell proliferation was analyzed by the alamarBlue
assay in IGF1R knockdown Hep3B cells infected with control or constitutively active AKT lentiviral particles and then treated with
1.25 lM sorafenib. Each experiment was repeated at least 3 times. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RFU, relative ﬂuorescence unit; shScr, short hairpin scrambled. Values in C and E were mean 6 SD (n 5 3 in each group).
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HCC cell lines (Fig. 1A). Phosphorylation of AKT
was also not decreased by sorafenib (Fig. 1A; Supporting Fig. S1B). However, phosphorylation of ERK, a
downstream target of RAF/mitogen-activated protein
kinase/ERK kinase (MEK),(29) was decreased after
sorafenib treatment, indicating sorafenib had activity
against ERK in all three HCC cell lines (Fig. 1A). To
determine whether IGF1R activity remains contributory to HCC cell growth and survival after sorafenib
treatment, we used lentiviral shRNAs to knock down
IGF1R expression in Hep3B cells. We found that
knockdown of IGF1R enhanced the inhibitory efﬁcacy
of sorafenib on Hep3B cell growth (Fig. 1B,C). Further, knockdown of IGF1R decreased the phosphorylation of AKT but not ERK in Hep3B cells (Fig. 1B).
To determine whether knockdown of IGF1R enhances
the inhibitory efﬁcacy of sorafenib on HCC cell
growth by inhibiting AKT activity, we overexpressed
constitutively active AKT in IGF1R knockdown cells
(Fig. 1D). We found that overexpression of constitutively active AKT abrogated the ability of IGF1R
knockdown to sensitize HCC cells to sorafenib (Fig.
1E). In general, these data indicate that knockdown of
IGF1R sensitizes HCC cells to sorafenib treatment by
inhibiting AKT activity.

CERITINIB ENHANCES THE
EFFICACY OF SORAFENIB IN
INHIBITING HCC CELL GROWTH
AND SURVIVAL
To determine whether the use of a combination
treatment using IGF1R inhibitors and sorafenib is a
viable clinical translational strategy to treat HCC, we
examined whether ceritinib, an FDA-approved dual
ALK and IGF1R inhibitor for the treatment of nonsmall cell lung cancer,(17,18) further sensitizes HCC
cells to sorafenib treatment. To do so, we ﬁrst examined the effect of ceritinib on HCC cell growth, which
has not been reported. We found that ceritinib effectively inhibited IGF1R activity, which was marked by
the phosphorylation of IGF1R and AKT, in HCC
cells. Interestingly, ERK phosphorylation was not
affected by ceritinib (Fig. 2A). As ceritinib is also an
ALK inhibitor, we examined whether ceritinib inhibits
ALK activity in a number of HCC cell lines, including
Hep3B, Huh7, and HepG2. We found that ALK
expression was too low to be detected in these cell lines
(Fig. 2A), suggesting that ALK does not play an
important role in the growth of these HCC cells. We
also found that ceritinib inhibited the growth of HCC
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cells (Fig. 2B), which phenocopies the effect of knockdown of IGF1R in HCC cells (Fig. 2C). In addition,
overexpression of constitutively active AKT abrogated
the inhibitory effect on HCC cell growth by either ceritinib or knockdown of IGF1R (Fig. 2D,E). These
results suggest that ceritinib suppresses HCC cell
growth by inhibiting the IGF1R/AKT pathway.
We next examined whether ceritinib enhances the
inhibitory efﬁcacy of sorafenib on HCC cell growth
and survival. Indeed, ceritinib enhanced the efﬁcacy of
sorafenib in inhibiting HCC cell growth in a doseand time-dependent manner (Fig. 3A,B). Further, we
found that ceritinib increased sorafenib-induced cellular apoptosis, marked by cleavage of caspase-3 and poly(adenosine diphosphate ribose) polymerase (Fig. 3C).
Collectively, our data indicate that ceritinib enhances
the inhibitory efﬁcacy of sorafenib on HCC cell
growth and survival.

CERITINIB ENHANCES THE
EFFICACY OF SORAFENIB IN
INHIBITING HCC CELL GROWTH
AND SURVIVAL BY INHIBITING
THE IGF1R/AKT PATHWAY
To determine whether ceritinib enhances the efﬁcacy of sorafenib in inhibiting HCC cell growth and
survival by inhibiting the IGF1R/AKT pathway, we
ﬁrst examined the levels of phosphorylated IGF1R and
AKT by western blotting. We found decreased phosphorylation of IGF1R in HCC cells treated with a
combination of ceritinib and sorafenib compared to
such cells treated with sorafenib alone (Fig. 4A). The
level of phosphorylated AKT was also decreased in
HCC cells treated with a combination of ceritinib and
sorafenib compared to such cells treated with sorafenib
alone (Fig. 4A), even when phosphorylation of AKT
was increased by sorafenib treatment in HepG2 and
Huh7 cells (Fig. 4A); this is consistent with results
reported by other groups.(5) Notably, the level of phosphorylated ERK was not further decreased by ceritinib
in HCC cells treated with a combination of ceritinib
and sorafenib compared to such cells treated with sorafenib alone (Fig. 4A). Importantly, overexpression of
constitutively active AKT rescued the ability of ceritinib to sensitize HCC cells to sorafenib treatment (Fig.
4B,C), suggesting that ceritinib enhances the efﬁcacy
of sorafenib in inhibiting HCC cell growth and survival by inhibiting the IGF1R/AKT pathway.
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FIG. 2. Ceritinib suppressed HCC cell growth by inhibiting the IGF1R/AKT pathway. (A) HCC cells were treated with ceritinib (0.5
lM for Hep3B, 1 lM for HepG2, and 2 lM for Huh7) for 24 hours. Expressions of p-IGF1R, IGF1R, p-AKT (ser473), AKT, p-ERK,
ERK, and GAPDH proteins were examined by western blotting. (B) HCC cells were treated with ceritinib at different doses for 48 hours.
Cell proliferation was analyzed by the alamarBlue assay. (C) Cell proliferation was analyzed by the alamarBlue assay in Hep3B cells infected
with IGF1R shRNAs and scrambled shRNA lentiviral particles. (D) Hep3B cells infected with control or constitutively active AKT lentiviral particles were treated with 0.5 lM ceritinib for 48 hours. Cells were then cultured for 14 days and stained with 0.5% crystal violet. (E)
Cell proliferation was analyzed by the alamarBlue assay in IGF1R knockdown Hep3B cells infected with control or constitutively active
AKT lentiviral particles. Each experiment was repeated at least 3 times. Abbreviations: DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RFU, relative ﬂuorescence unit. Values in B, C, D, and E were mean 6 SD (n 5 3 in each group).
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FIG. 3. Ceritinib enhanced the efﬁcacy of sorafenib in inhibiting HCC cell growth and survival in vitro. (A) Hep3B, HepG2, or Huh7
cell numbers were counted following treatment with sorafenib or a combination of sorafenib and ceritinib for varying lengths of time. *P
< 0.05; **P < 0.01; ***P < 0.001. (B) Viability of Hep3B, HepG2, and Huh7 cells was analyzed by the alamarBlue assay 48 hours following treatment with sorafenib or a combination of sorafenib and ceritinib. (C) Expressions of cleaved caspase-3, caspase-3, PARP, and
b-actin proteins were examined by western blotting in Hep3B and HepG2 cells treated with vehicle, sorafenib, ceritinib, or a combination of both. Each experiment was repeated at least 3 times. Abbreviations: C, ceritinib; D, dimethyl sulfoxide; DMSO, dimethyl sulfoxide; PARP, poly(adenosine diphosphate ribose) polymerase; S, sorafenib. Values in A and B were mean 6 SD (n 5 3 in each group).
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FIG. 4. The combination of ceritinib and sorafenib inhibited HCC cell growth by inhibiting the IGF1R/AKT pathway. (A) Expressions of p-IGF1R, IGF1R, p-AKT, AKT, and GAPDH proteins in Hep3B, HepG2, and Huh7 cells following treatment with
DMSO, sorafenib, ceritinib, or a combination of both drugs for 24 hours were examined by western blotting. (B) Hep3B cells infected
with control or constitutively active AKT lentiviral particles were treated with DMSO, ceritinib, sorafenib, or a combination of both
drugs for 48 hours. Cells were then cultured for 14 days and stained with 0.5% crystal violet. (C) Colonies from (B) were quantiﬁed.
Each experiment was repeated at least 3 times. Abbreviations: C, ceritinib; D, dimethyl sulfoxide; DMSO, dimethyl sulfoxide;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; S, sorafenib. Values in C were mean 6 SD (n 5 3 in each group).


CERITINIB ENHANCES THE
EFFICACY OF SORAFENIB IN
INHIBITING HCC TUMOR
GROWTH IN VIVO
To further investigate the efﬁcacy of ceritinib in sensitizing HCC cells to sorafenib treatment in vivo, we
ﬁrst examined the effect of the combination of ceritinib
and sorafenib in a xenograft model. We found that
treatment with either ceritinib or sorafenib alone was
able to inhibit tumor growth while combination treatment using ceritinib and sorafenib had the best overall
effectiveness (Fig. 5A-C). Importantly, mouse weight
was not signiﬁcantly affected by the combination
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treatment, suggesting minimal toxicity for the combination treatment regimen (Fig. 5D). We further conﬁrmed that ceritinib treatment inhibited IGF1R and
AKT activities in xenografted tumors (Fig. 5E). Additionally, we found that combination treatment with
ceritinib and sorafenib further decreased tumor cell
proliferation (Fig. 5F) and increased tumor cell
apoptosis (Fig. 5G; Supporting Fig. S2) compared to
sorafenib or ceritinib treatment alone. Overall, our
xenograft model results demonstrate that ceritinib
enhances the efﬁcacy of sorafenib in inhibiting human
HCC tumor growth.
To further test the efﬁcacy of ceritinib in sensitizing
HCC cells to sorafenib treatment in a mouse model



FIG. 5. Ceritinib enhanced the efﬁcacy of sorafenib-mediated inhibition of HCC tumor growth in a xenograft model. (A) Hep3B
cells were injected into SCID-bg mice subcutaneously to construct a xenograft model. Two weeks after injection, ﬁve mice were
treated with vehicle (30% captisol), ceritinib (25 mg/kg), sorafenib (25 mg/kg), or combination of ceritinib and sorafenib daily by oral
gavage for two weeks. Tumor volumes were measured daily using external calipers until the day of sacriﬁce. Gross tumors were photographed after harvesting (magniﬁcation, 1x). (B) Tumor weights of the mice from (A). (C) Tumor volumes from the mice from (A).
Mice were weighed before and after treatment. (D) Mouse weight ratios (after/prior to treatment) of the mice from (A). (E) Expressions of p-IGF1R, IGF1R, p-AKT, AKT, and GAPDH proteins in tumors from (A) were examined by western blotting. (F) Proliferation in tumors from (A) was examined by immunohistochemistry for Ki67. (G) Apoptosis in tumors from (A) was examined by
TUNEL staining. Each experiment was repeated at least 3 times. Abbreviations: C, ceritinib; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; IHC, immunohistochemistry; S, sorafenib; V, vehicle. Values in B, C, D, F, and G were mean 6 SD (n 5 5 for B-D
in each group, and n 5 3 for F and G in each group).




FIG. 6. Ceritinib enhanced the efﬁcacy of sorafenib in inhibiting tumor growth in the MET/CAT-driven HCC model. (A) Expressions of
p-IGF1R, IGF1R, p-AKT, AKT, and GAPDH proteins were detected by western blotting in the livers of ﬁve C57B6/J mice 8 weeks after
hydrodynamic injection of MET/CAT or pT3 control. (B) Photographs (magniﬁcation, 0.5x) and H&E staining of livers of C57B6/J mice 6
weeks after injection of MET/CAT followed by treatment with vehicle (30% captisol), ceritinib (25 mg/kg), sorafenib (25 mg/kg), or a combination of ceritinib and sorafenib for 4 weeks. (C) Liver weight/body weight ratios were analyzed in mice from (B) (n 5 5). (D) Mouse weight
ratios (after/prior to treatment) of mice from (B) (n 5 5). (E) Expressions of p-IGF1R, IGF1R, p-AKT, AKT, and GAPDH proteins in
mice from (B) were examined by western blotting. (F) Proliferation in liver tumors from (B) was examined by immunohistochemistry for
Ki67. (G) Apoptosis in liver tumors from (B) was examined by TUNEL staining. Each experiment was repeated at least 3 times. Abbreviations: C, ceritinib; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H&E, hematoxylin and eosin; IHC, immunohistochemistry; S, sorafenib; V, vehicle. Values in C, D, F and G were mean 6 SD (n 5 5 for C and D in each group, and n 5 3 for F and G in each group).
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FIG. 7. Schematic model. Sorafenib inhibits its downstream targets RAF, VEGF, and PDGF, resulting in inhibition of MEK/ERK
activity, which leads to inhibition of HCC cell proliferation and survival. However, HCC cells are able to escape from sorafenib’s
effects using other resistance pathways that sorafenib insufﬁciently inhibits. IGF1R/AKT is such a sorafenib-resistant pathway.
IGF1R remains activated after sorafenib treatment in HCC cells and its activity leads to AKT activation, which is critical for HCC
cell proliferation and survival. Ceritinib is a potent IGF1R inhibitor. Ceritinib effectively inhibits the IGF1R/AKT pathway but fails
to suppress ERK activity. Therefore, ceritinib alone has a modest effect on HCC cell proliferation and survival. The combination of
sorafenib and ceritinib effectively inhibits both the MEK/ERK and IGF1R/AKT pathways, which results in more effective inhibition
of HCC cell growth compared to either sorafenib or ceritinib used alone. Abbreviations: MEK, mitogen-activated protein kinase/
ERK kinase; PDGF, platelet-derived growth factor.


with intact immune responses, we used the MET/
CAT-driven HCC model. Co-activation of MET and
b-catenin often occurs in HCC.(22) Codelivery of both
MET and CAT (DN90-b-catenin, exon 3 deleted),
but neither MET nor CAT alone, into mouse livers
using the sleeping beauty transposon system efﬁciently
induces HCC within several weeks.(22-24) Therefore,
this model (referred to here as MET/CAT) is useful
for studying the functions of genes in hepatocarcinogenesis because of its clinical relevance and efﬁciency

of HCC induction. We found that both IGF1R and
AKT are activated in MET/CAT-induced HCCs
(Fig. 6A). We injected C57B6/J mice with MET/
CAT to induce HCC and then treated them with
vehicle, ceritinib, sorafenib, or a combination of both
drugs for 4 weeks. Consistent with the results from our
xenograft model, either ceritinib or sorafenib when
used alone was able to inhibit HCC development, but
the combination treatment had the best efﬁcacy in
tumor inhibition (Fig. 6B,C; Supporting Fig. S3).
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Mouse weights also were not signiﬁcantly changed by
the combination treatment, suggesting tolerable toxicity of the combination treatment in mice with intact
immune responses (Fig. 6D). Phosphorylation of both
IGF1R and AKT was also inhibited by ceritinib treatment in MET/CAT-induced tumors (Fig. 6E). Furthermore, combination treatment with ceritinib and
sorafenib decreased tumor cell proliferation (Fig. 6F)
and increased tumor cell apoptosis (Fig. 6G) compared
to ceritinib or sorafenib monotherapy in this model.
Overall, our data demonstrate that ceritinib enhances
the efﬁcacy of sorafenib in inhibiting HCC tumor
growth in preclinical mouse models with intact
immune responses.

Discussion
HCC is a common and fatal malignancy of the liver
and is the second leading cause of cancer-related mortality in the world.(1,30) Sorafenib, the ﬁrst-line oral
therapeutic agent for advanced HCC increases patient
survival by less than 3 months. Regorafenib was
recently approved by the FDA for treatment of
patients with HCC who do not or no longer respond
to sorafenib, but it only increases survival by about 3
months.(31) Nivolumab, a programmed cell death protein 1 inhibitor, also was approved to treat sorafenibtreatment failures, but the overall response rate was
only 14.3% (22/154) (http://www.opdivohcp.com/
advanced-hcc/efﬁcacy/clinical-trial-results). Therefore,
there is still an urgent need to develop new and more
effective therapeutic agents and strategies to treat
HCC. In this study, we demonstrate that inhibition of
IGF1R efﬁciently increases sensitivity of HCC cells to
sorafenib treatment in in vitro and in vivo models.
The ﬁndings of the current study provide a basis to
investigate a new combination of sorafenib with an
IGF1R inhibitor, such as ceritinib, for treatment of
HCC.
IGFIR overactivation is one of the hallmarks of
HCC and can be mediated by increased levels of
IGFIR protein and/or an excess of IGF ligands.(32)
Healthy mature hepatocytes do not express IGFIR.(16)
In HCC samples, up-regulation of IGFIR is one of
the most common alterations, occurring in 30% of
patients.(33) Activation of IGFIR signaling in HCC
was signiﬁcantly associated with AKT and mammalian
target of rapamycin signaling.(16) In vitro studies
showed that abrogation of IGF1R activation and
downstream signaling by the monoclonal antibody

744

HEPATOLOGY COMMUNICATIONS, June 2018

A12 signiﬁcantly decreased cell viability and proliferation.(14) In vivo, A12 delayed tumor growth and prolonged survival, reducing proliferation rates and
inducing apoptosis.(14) Although several IGF1R inhibitors or blocking antibodies have been tested in preclinical models or clinical trials for patients with
HCC,(9,14-16) none has been approved by the FDA,
possibly because inhibition of IGF1R alone may not
be sufﬁcient to effectively inhibit HCC cell growth
and survival. Our data support this hypothesis as inhibition of IGF1R by shRNA or ceritinib has only a
modest suppression on HCC proliferation and survival
(Figs. 1 and 2). However, we show for the ﬁrst time
that the combination of sorafenib and the IGF1R
inhibitor ceritinib is more effective against HCC in in
vitro and in vivo models compared to sorafenib or
inhibition of IGF1R alone. The addition of an IGF1R
inhibitor is advantageous because sorafenib is insufﬁcient to inhibit IGF1R and downstream AKT activation in HCC cells and IGF1R is critical for AKT
activation, which promotes HCC cell proliferation and
survival.(34) Combination treatment using sorafenib
and IGF1R inhibitors not only suppresses plateletderived growth factor receptor, VEGFR, and RAF
phosphorylation but also inhibits the IGF1R/AKT
axis, resulting in a more efﬁcacious anti-HCC effect
(Fig. 7).
Ceritinib is well known as an adenosine
triphosphate-competitive tyrosine kinase inhibitor of
ALK. Intriguingly, the expression of both ALK (Fig.
2A) and p-ALK in the HCC cell lines (Hep3B,
Huh7, and HepG2) is very low (data not shown).
Therefore, it is unlikely that ceritinib sensitizes these
HCC cells to sorafenib by inhibiting ALK. Two recent
studies indicate that ALK is overexpressed in 13%44% human HCC and that this overexpression is correlated with poor prognosis.(35,36) ALK can be activated by different ligands (e.g., growth factors
pleiotrophin or midkine) and various pathways.(37)
Therefore, it is likely that ceritinib inhibits ALK activity in some patients with HCC. We found that overexpression of ALK decreases the sensitivity of HCC cells
to sorafenib (data not shown), suggesting inhibition of
ALK might sensitize HCC cells to sorafenib. Therefore, combination therapy consisting of ceritinib plus
sorafenib might be suitable not only for patients with
HCC with activated IGF1R but also for a subset of
patients with HCC with ALK activation as well as for
patients showing both IGF1R and ALK activation.
It has been shown that IGF1R activation leads to
both PI3/AKT and RAS/RAF/ERK activation.(8)
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However, we found that knockdown of IGF1R or ceritinib inhibits only the activation of AKT but not ERK
in HCC cells (Fig. 2A). The failure to inhibit ERK
activity may explain why knockdown of IGF1R or the
use of ceritinib alone has a modest effect on HCC cell
growth and survival. On the other hand, sorafenib
treatment is sufﬁcient to effectively inhibit ERK activity but not AKT activity in HCC cells (Fig. 1A).
Therefore, the combined use of sorafenib and ceritinib
leads to inhibition of both ERK and AKT activities,
which results in profound inhibition of HCC cell
growth and ultimately cell death (Fig. 7). The mechanisms by which IGF1R inhibition fails to abrogate
ERK activity in HCC cells remain unclear. It has been
shown that A12, a monoclonal antibody against
IGF1R, failed to inhibit ERK in leukemic cells treated
with interleukin-3.(38) Therefore, it is possible that
ERK can be activated by other upstream factors, such
as interleukin-3, and that IGF1R is not a major regulator of ERK activation in HCC cells.
In conclusion, our study shows that IGF1R inhibition effectively sensitizes HCC cells to sorafenib treatment by inhibiting AKT activity. The combined
inhibition of IGF1R using ceritinib and sorafenib may
offer an improved strategy to treat HCC. As ceritinib
is already FDA approved, a clinical trial using combination treatment with sorafenib is warranted. A number of IGF1R inhibitors have been developed and are
being studied in clinical trials for multiple types of
solid tumors. A combination of one of these inhibitors
plus sorafenib might provide a new direction in HCC
therapy, especially in patients with activated IGF1R.
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